Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • laquinimod

    - PMLiVE

    Genentech announces positive clinical results for BTK inhibitor MS treatment

    Multiple sclerosis affects more than 2.9 million people globally

    - PMLiVE

    Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study

    The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease

    - PMLiVE

    Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

    The neurological disorder affects more than 150,000 people in the UK

    - PMLiVE

    Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS

    The neurological disorder affects approximately 2.9 million people globally

    - PMLiVE

    Sanofi shares positive late-stage results for investigational BTK inhibitor in progressive MS

    Tolebrutinib is currently being evaluated in various forms of the neurological disorder

    - PMLiVE

    Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS

    The subcutaneous formulation has the same twice-yearly dosing schedule as the previously approved intravenous infusion

    - PMLiVE

    Roche shares positive 48-week results for investigational BTK inhibitor in relapsing MS

    Approximately 2.9 million people worldwide are affected by the neurological disease

    - PMLiVE

    Sanofi’s investigational BTK inhibitor tolebrutinib shows promise in phase 3 MS study

    The neurological disorder affects approximately 2.9 million people worldwide

    - PMLiVE

    FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar

    Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease

    - PMLiVE

    Study suggests self-reported information could help predict MS progression

    Predicting MS progression could improve treatment and care outcomes for patients

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links